Elevating Our Communities With Every Interaction

Velocity is the world's leading integrated site organization.

Sponsors and CROs trust Velocity to deliver high-quality clinical trial data and patient care with unprecedented efficiency.

Simplify everything from site selection to study close-out

Velocity unifies operational processes to provide world-class sites, reliable enrollment, and predictably high performance for your trials.

+
Research sites across the U.S. and Europe
+
Investigators with diverse experience
+
Clinical trials conducted since 1986
U.S. Department of Health and Human Services (HHS) Officials Meet With Leaders to Discuss COVID-19 Vaccine Clinical Trials and Patient Recruitment
mother-and-child-2
Hallandale
caring african medical nurse comforting senior patient in office
Velocity-team-office

The right sites.
The right investigators.
The right partner for you.

Strategically located to give you access to diverse specialty populations, Velocity's sites are supported by next-gen technologies and patient engagement capabilities. Welcome to recruitment and retention reimagined.

Scale for a purpose: Supporting research programs worldwide

From the leading pharma companies, to the most pioneering biotech startups, Velocity supports those who are exploring new frontiers in human health.

Whether you’re ready to conduct a single-site study or a complex, high-volume clinical trial, contact Velocity.

News

Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache

July 17, 2025

Velocity Clinical Research, the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies to automate and streamline the notoriously complex payments reconciliation process in clinical trials. … Read more

Velocity Recognized as a Top Enrolling Site Network in Q1 2025 by AstraZeneca

July 16, 2025

We’re proud to share that Velocity was named a top enrolling site network for Q1 2025 by AstraZeneca, with the highest number of randomizations across their biopharma portfolio. This recognition … Read more

Douglas K. Logan, MD, and David Ensz, MD, Author Nature Communications Article

July 3, 2025

Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin … Read more

An interview with Daniel Williams, DO on Velocity’s PIVOT program and training the next generation of Principal Investigators

July 2, 2025

Very few physicians begin their careers with an eye on research. Moving into the role of Principal Investigator (PI) can be unexpectedly challenging, with demands that often take physicians by … Read more

Quality. Continuity. Velocity.